Stiris Research Inc. Announces the Award of a Phase II Vasculitis Study

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces the award of a Phase II Vasculitis study.

“We are excited to have the opportunity to work on this vasculitis trial. This investigational product looks to be a promising option for a patient population that can suffer from severe health outcomes. We are looking forward to continued collaboration with this Sponsor in bringing a promising therapeutic to the table.” said Shantal Feltham, President & CEO.

Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can result in organ and tissue damage. Vasculitis can affect anyone, though some types are more common among certain age groups. Depending on the type you have, you may improve without treatment. Most types require medications to control the inflammation and prevent flare-ups. (https://www.mayoclinic.org/diseases-conditions/vasculitis/symptoms-causes/syc-20363435)